Anebulo Pharmaceuticals (NASDAQ:ANEB) Given Speculative Buy Rating at Benchmark

Benchmark reaffirmed their speculative buy rating on shares of Anebulo Pharmaceuticals (NASDAQ:ANEB) in a research note issued to investors on Tuesday morning, Benzinga reports. Benchmark currently has a $8.00 price target on the stock.

Anebulo Pharmaceuticals Trading Up 2.8 %

Shares of ANEB stock opened at $1.98 on Tuesday. The stock has a 50 day simple moving average of $2.03 and a 200-day simple moving average of $2.34. The company has a market cap of $51.47 million, a price-to-earnings ratio of -5.36 and a beta of -1.01. Anebulo Pharmaceuticals has a 12-month low of $1.62 and a 12-month high of $3.61.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last released its quarterly earnings data on Wednesday, September 25th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.08. On average, equities analysts forecast that Anebulo Pharmaceuticals will post -0.48 earnings per share for the current fiscal year.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.